Summary
The glucagon receptor antagonist LY2409021 (LY) substantially lowers HbA1C without severe hypoglycemia or weight gain in type 2 diabetes mellitus (T2DM) patients. In a double-blind, randomized, placebo-controlled, Phase 2 study researchers examined the margin between LY efficacy and safety by comparing mean changes in HbA1C and liver aminotransferases at 3 dose levels.
- Diabetes & Endocrinology Clinical Trials
- Hyperglycemia/Hypoglycemia
- Diabetes Mellitus
- © 2012 MD Conference Express®
Tools
12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus
Permalink:
Table of contents
Cited By...
- No citing articles found.